Introduction {#s2}
============

The use of thiazolidinedione antidiabetic agents has become widespread in the treatment of type 2 diabetes since their introduction in the late 1990s, although recently the safety of this class of medicines has been called into question [@pmed.1000154-Nissen1]--[@pmed.1000154-Singh1]. Although most attention has focused on the possible vascular effects of thiazolidinediones, the ADOPT trial of rosiglitazone also detected a 2-fold increased risk of fractures among patients treated with rosiglitazone [@pmed.1000154-Kahn1]. Similar effects were seen in a pooled analysis of pioglitazone trials [@pmed.1000154-US1], suggesting a possible class effect. Surprising---and unexplained---features of the observed increased fracture risk in clinical trials were that the risk appeared to mainly involve fractures of the arm, hand, wrist, or foot, and that the increased risk was restricted to women. However, the individual clinical trials did not have adequate statistical power to reliably assess fracture risk. People prescribed and not prescribed thiazolidinediones are likely to differ in ways that are difficult to measure and control for, making most observational studies subject to confounding and difficult to interpret. We therefore applied the self-controlled case-series design (a within-person approach) to assess the risk of fracture associated with thiazolidinedione use. This approach eliminates fixed (non-time-varying) between-person confounding, which is not the case with alternative case-control or cohort designs [@pmed.1000154-Whitaker1]. The study was based on primary care computerized clinical records from the United Kingdom-based General Practice Research Database (GPRD).

Methods {#s3}
=======

The General Practice Research Database {#s1a}
--------------------------------------

The GPRD contains information from over 6 million patients registered at over 400 computerised general practice surgeries in the UK [@pmed.1000154-Lawson1],[@pmed.1000154-General1]. Continuous information is recorded for each patient including a record of each consultation, any diagnoses made, all prescribed medicines, and basic demographic data. The geographical distribution and size of GP practices represented in GPRD is largely representative of the population of England and Wales, and the individuals registered on the database are representative of the whole UK population in terms of age and sex [@pmed.1000154-Office1]. The quality of data held in the GPRD is subject to rigorous checks and regular audits and it has been successfully used to conduct over 500 peer-reviewed published studies. The information obtained from the database is entirely anonymous. Ethical approval for this study was obtained from the Independent Scientific Advisory Group of the General Practice Research Database and the London School of Hygiene and Tropical Medicine Ethics Committee.

Selection of Participants {#s2b}
-------------------------

Patients were selected from the population registered with the GPRD up to 4 April 2007. Eligible participants were all those with both a diagnosis of fracture and a first recorded thiazolidinedione prescription at least 12 mo after initial registration with the GPRD.

Self-controlled Case-Series Design {#s2c}
----------------------------------

The self-controlled case-series design method is derived from rate modelling using a Poisson distribution and is therefore comparable with cohort methodology. Only cases are included; thus the modelling is conditional on people experiencing the outcome in question (here, diagnosis of fracture) at some stage. It relies on within-person comparisons in a population of individuals who have both the outcome and exposure of interest [@pmed.1000154-Whitaker1],[@pmed.1000154-Farrington1]. Incidence rate ratios are derived, comparing the rate of events during exposed periods of time with the rate during all other observed time periods. A major advantage of this design is that the potential confounding effect of both recorded and unrecorded fixed characteristics that vary between individuals, such as frailty, is removed.

For each participant, we identified all thiazolidinedione prescriptions. The length of exposure following each individual prescription was calculated using information recorded in GPRD on pack size and dosing frequency. From all prescription records where this information was available, the median length of exposure from a single prescription was calculated. This median duration was imputed for all individual prescriptions where duration was not recorded. Thiazolidinedione treatment was assumed to be continuous where any apparent treatment break was less than 60 d, to allow for partial noncompliance and situations where patients may have built up treatment stocks. Follow-up time was then censored at the earliest of any treatment break longer than 60 d or the end of recorded follow up in the database. A mechanism for thiazolidinedione-induced fractures has not yet been established and so it is not clear whether the influence of thiazolidinediones is short lived or maintained long after treatment cessation. By censoring follow up at a prolonged treatment break we do not make any assumptions about the duration of influence and therefore avoid bias owing to misclassification of exposure. The period prior to the first thiazolidinedione prescription was classified as the baseline, unexposed period. A representation of exposure periods is shown in [Figure 1](#pmed-1000154-g001){ref-type="fig"}.

![Representation of study design.\
The figure illustrates a single individual prescribed a thiazolidinedione during their observation period. All participants included in the analysis had at least one prescription for a thiazolidinedione and at least one fracture. The rate ratios presented are pooled estimates derived from the rate of events during the risk (exposed) periods divided by the rate of events during the baseline periods. Age is adjusted for at all stages of the analysis.](pmed.1000154.g001){#pmed-1000154-g001}

Recorded fractures were classified according to fracture site (ankle, arm, chest/rib, face, foot, hand, hip, leg, pelvis, shoulder, skull, wrist, spine, multiple sites, unknown site). Where more than one fracture was recorded for a patient, we assumed each fracture was incident if it occurred at a different site to the previous fracture, or was recorded more than 6 mo after a fracture at the same site.

Analysis using the self-controlled case-series design inherently takes duration of follow up into account. We estimated relative rate ratios for fracture using conditional Poisson regression with Stata Version 9 software (StataCorp), adjusting for age at first thiazolidinedione prescription in 1-y bands. We first assessed the impact of exposure to any thiazolidinedione on fracture at any site. We also looked for evidence of sex differences, the differential effects of rosiglitazone and pioglitazone, the effect of thiazolidinedione exposure duration, and the effect on fractures at specific sites: (1) arm, wrist, hand, and foot; (2) hip; (3) spine.

For validation purposes we also assessed the association between treatment with a sulphonylurea and fracture at any site as we had no a priori reason to suspect an association. The same study population was used, but exposed periods were defined as periods where the patient was receiving any sulphonylurea. For this analysis, follow up was censored at the date of first thiazolidinedione prescription.

Results {#s4}
=======

We identified 1,819 patients in the GPRD prescribed at least one thiazolidinedione and with a record of at least one fracture and background details for these patients are shown in [Table 1](#pmed-1000154-t001){ref-type="table"}. 1,356 patients received only prescriptions for rosiglitazone, 389 received only pioglitazone, and the remaining 74 received prescriptions for both rosiglitazone and pioglitazone at different times. 990 (54%) were female and the mean age at first thiazolidinedione exposure was 57.9 y for men and 65.4 y for women. The mean duration of unexposed follow up prior to thiazolidinedione use was 9.5 y, and the mean duration of exposure to a thiazolidinedione was 2.3 y. Arm, foot, wrist, or hand fractures were recorded for 905 patients, hip fractures for 150 patients, and spine fractures in 66 patients. The remaining 733 patients had fractures at other sites. Patients with hip and spine fractures tended to be older at first thiazolidinedione prescription: mean age of 70.5 y and 65.6 y for patients with hip and spine fractures, respectively. Regarding multiple fractures, 283 (16%), 64 (4%), and 25 (1%) had two, three, and four or more fractures, respectively.

10.1371/journal.pmed.1000154.t001

###### Demographic details of study population.

![](pmed.1000154.t001){#pmed-1000154-t001-1}

  Patient Group         *n* Patients with at least One Fracture at Any Site   Mean Age at Start of Glitazone Exposure (y)[a](#nt101){ref-type="table-fn"}   *n* Fractures before Glitazone Exposure[b](#nt102){ref-type="table-fn"}   Duration (mean y) of Follow up Pre-Glitazone Exposure[a](#nt101){ref-type="table-fn"}   *n* Fractures during Glitazone Exposure[b](#nt102){ref-type="table-fn"}   Duration (Mean y) of Glitazone Exposure[a](#nt101){ref-type="table-fn"}
  -------------------- ----------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------
  Any glitazone                                1,819                                                          62.0 (12.8)                                                                    1,546                                                                          9.5 (4.6)                                                                           720                                                                    2.3 (1.7)
  Female                                        990                                                           65.4 (12.1)                                                                     825                                                                           9.2 (4.6)                                                                           445                                                                    2.4 (1.7)
  Male                                          829                                                           57.9 (12.3)                                                                     722                                                                           9.8 (4.6)                                                                           274                                                                    2.3 (1.7)
  Rosiglitazone only                           1,356                                                          62.2 (13.0)                                                                    1,138                                                                          9.4 (4.6)                                                                           542                                                                    2.3 (1.7)
  Pioglitazone only                             389                                                           61.7 (12.3)                                                                     347                                                                           9.6 (4.5)                                                                           149                                                                    2.3 (1.6)

Standard deviation given in parentheses.

Some patients had more than one fracture.

Absolute rates of fracture are uninformative in this study since selection is restricted by design to patients who have had a fracture. The crude rate ratio for any fracture at any site, comparing thiazolidinedione exposed versus unexposed period was 1.70 (95% confidence interval \[CI\] 1.53--1.88), but this does not take into account the fact that each participant is older in the exposed period. We detected an annual increase in the rate of all fractures of approximately 5% when the effect of age was considered alone (rate ratio for a 1-y increase in age = 1.05, 95% CI 1.04--1.06). After adjustment for age in single year bands, the adjusted rate ratio for the association between thiazolidinediones and fracture was 1.43 (95% CI 1.25--1.62) comparing exposed with unexposed periods ([Table 2](#pmed-1000154-t002){ref-type="table"}). There was no evidence that the association varied by sex; the age-adjusted rate ratio for all fracture types amongst patients receiving any thiazolidinedione was 1.42 (1.20--1.69) for females and 1.44 (1.18--1.77) for males. When thiazolidinedione exposure was stratified by duration, the rate ratio for all fractures increased steadily from 1.26 (1.07--1.47) during the first year to 2.00 (1.48--2.70) during years four to seven. Fracture-site specific analyses for all thiazolidinedione users revealed a rate ratio of 1.28 (1.05--1.56) for arm, wrist, hand, or foot fractures, 2.09 (1.29--3.40) for hip fractures, and 2.72 (1.29--5.73) for spine fractures. There was no evidence that the rate ratio varied by gender. In patients who only received rosiglitazone, the rate ratio for fracture at any site was 1.49 (1.28--1.74), and amongst those who only received pioglitazone the rate ratio was 1.26 (0.95--1.68) ([Table 3](#pmed-1000154-t003){ref-type="table"}). A test for interaction showed no evidence that the effect varied by thiazolidinedione type (*p* = 0.47). The rate ratios for fractures at specific sites were also similar for each thiazolidinedione ([Table 3](#pmed-1000154-t003){ref-type="table"}).

10.1371/journal.pmed.1000154.t002

###### Case-series analysis for thiazolidinediones: association between exposure to any thiazolidinedione and fractures.

![](pmed.1000154.t002){#pmed-1000154-t002-2}

  Fracture Site                                                              Exposure          Patient Years   *n* Fractures   Age-Adjusted Rate Ratio for Fracture (95% CI
  ------------------------------------------------------------------- ----------------------- --------------- --------------- ----------------------------------------------
  Fracture at any site                                                                                                        
  All patients (*n* = 1,819)                                             Unexposed periods        17,221           1,546                         Baseline
                                                                       Exposed periods (all)       4,240            720                     1.43 (1.25--1.62)
  Thiazolidinedione exposure period[a](#nt103){ref-type="table-fn"}    0--1 y (*n* = 1,819)        1,600            235                     1.26 (1.07--1.47)
                                                                       1--2 y (*n* = 1,325)        1,087            179                     1.49 (1.24--1.79)
                                                                        2--3 y (*n* = 874)          714             127                     1.70 (1.37--2.12)
                                                                        3--4 y (*n* = 564)          446             104                     2.31 (1.80--2.97)
                                                                        4--7 y (*n* = 342)          392             75                      2.00 (1.48--2.70)
  Females (*n* = 990)                                                    Unexposed periods         9,103            824                          Baseline
                                                                          Exposed periods          2,357            446                     1.42 (1.20--1.69)
  Males (*n* = 829)                                                      Unexposed periods         8,118            722                          Baseline
                                                                          Exposed periods          1,883            274                     1.44 (1.18--1.77)
  Foot, arm, wrist, or hand fracture                                                                                          
  All patients (*n* = 905)                                               Unexposed periods         8,599            735                          Baseline
                                                                          Exposed periods          2,102            284                     1.28 (1.05--1.56)
  Females (*n* = 519)                                                    Unexposed periods         4,837            411                          Baseline
                                                                          Exposed periods          1,227            183                     1.26 (0.98--1.62)
  Males (*n* = 386)                                                      Unexposed periods         3,762            324                          Baseline
                                                                          Exposed periods           876             101                     1.28 (0.93--1.77)
  Hip fracture                                                                                                                
  All patients (*n* = 150)                                               Unexposed periods         1,317            71                           Baseline
                                                                          Exposed periods           394             87                      2.09 (1.29--3.40)
  Females (*n* = 105)                                                    Unexposed periods          862             45                           Baseline
                                                                          Exposed periods           280             66                      2.09 (1.17--3.72)
  Males (*n* = 45)                                                       Unexposed periods          456             26                           Baseline
                                                                          Exposed periods           113             21                      1.90 (0.74--4.91)
  Spine fracture                                                                                                              
  All patients (*n* = 66)                                                Unexposed periods          624             41                           Baseline
                                                                          Exposed periods           155             29                      2.72 (1.29--5.73)
  Females (*n* = 34)                                                     Unexposed periods          311             21                           Baseline
                                                                          Exposed periods           82              15                      2.34 (0.77--7.13)
  Males (*n* = 32)                                                       Unexposed periods          313             20                           Baseline
                                                                          Exposed periods           73              14                      3.53 (1.18--10.58)

Test for trend (*p*\<0.01).

10.1371/journal.pmed.1000154.t003

###### Case-series analysis for thiazolidinediones: association between exposure to specific thiazolidinediones and fractures.

![](pmed.1000154.t003){#pmed-1000154-t003-3}

  Fracture Site                             Exposure        Patient Years   *n* Fractures     Age-Adjusted Rate Ratio for Fracture (95% CI)
  ------------------------------------ ------------------- --------------- --------------- ---------------------------------------------------
  Fracture at any site                                                                     
  Rosiglitazone (*n* = 1,356)           Unexposed periods      12,772           1,139                           Baseline
                                         Exposed periods        3,180            543        1.49 (1.28--1.74)[a](#nt105){ref-type="table-fn"}
  Pioglitazone (*n* = 389)              Unexposed periods       3,747            347                            Baseline
                                         Exposed periods         892             149        1.26 (0.95--1.68)[a](#nt105){ref-type="table-fn"}
  Foot, arm, wrist, or hand fracture                                                       
  Rosiglitazone (*n* = 675)             Unexposed periods       6,446            539                            Baseline
                                         Exposed periods        1,564            211                        1.30 (1.03--1.64)
  Pioglitazone (*n* = 188)              Unexposed periods       1,748            158                            Baseline
                                         Exposed periods         446             61                         1.43 (0.92--2.22)
  Hip fracture                                                                             
  Rosiglitazone (*n* = 115)             Unexposed periods       1,004            56                             Baseline
                                         Exposed periods         310             66                         1.80 (1.03--3.15)
  Pioglitazone (*n* = 32)               Unexposed periods        282             13                             Baseline
                                         Exposed periods         75              20                         2.65 (0.81--8.70)
  Spine fracture                                                                           
  Rosiglitazone (*n* = 53)              Unexposed periods        492             33                             Baseline
                                         Exposed periods         132             24                         3.13 (1.35--7.21)
  Pioglitazone (*n* = 11)               Unexposed periods        107              7        
                                         Exposed periods         18               4                 [\*](#nt106){ref-type="table-fn"}

Patients exposed to both thiazolidinediones excluded.

Test for interaction (*p* = 0.47).

**\*:** Insufficient outcomes to calculate rate ratio.

Bias can be introduced to a self-controlled case-series analysis if follow up is curtailed because of the event of interest in a substantial number of cases (e.g., due to a fatal outcome). For this reason a sensitivity analysis was performed for any fracture at any site, excluding patients who died during their observation period (*n* = 155). The rate ratio for thiazolidinedione exposed versus unexposed periods in this subgroup was 1.39 (1.21--1.59). Fracture-site specific analyses also yielded very similar results when patients who died were excluded.

A series of further sensitivity analyses were conducted: (1) censoring follow up in November 2006, prior to publication of the ADOPT study results highlighting fractures as a possible risk with rosiglitazone [@pmed.1000154-Kahn1]; (2) restricting follow up to 2000 onwards, when thiazolidinediones were first available in the UK; and (3) restricting analysis to 2 y prior to and post first thiazolidinedione prescription. These three sensitivity analyses had no material effect on our results.

The self-controlled case-series analysis was repeated using the same study population, but measuring the association between all fracture types and exposure to sulphonylureas rather than thiazolidinediones ([Table 4](#pmed-1000154-t004){ref-type="table"}). 694 relevant patients were identified and the rate ratio for fracture at any site amongst all patients prescribed a sulphonylurea was 0.84 (0.66--1.08). There was no evidence that the association varied with sulphonylurea exposure duration up to 7 y.

10.1371/journal.pmed.1000154.t004

###### Case-series analysis for sulphonylureas: association between exposure to any sulphonylurea and fractures.

![](pmed.1000154.t004){#pmed-1000154-t004-4}

  Fracture at Any Site                                                   Exposure          Patient Years   *n* Fractures   Age-Adjusted Rate Ratio for Fracture (95% CI)
  --------------------------------------------------------------- ----------------------- --------------- --------------- -----------------------------------------------
  All patients (*n* = 694)                                           Unexposed periods         4,117            490                          Baseline
                                                                   Exposed periods (all)       2,408            348                      0.84 (0.66--1.08)
  Sulphonylurea exposure period[a](#nt107){ref-type="table-fn"}    0--1 year (*n* = 694)        597             102                      0.89 (0.69--1.16)
                                                                    1--2 y (*n* = 520)          460             61                       0.77 (0.56--1.05)
                                                                    2--3 y (*n* = 405)          357             53                       0.94 (0.67--1.31)
                                                                    3--4 y (*n* = 305)          267             43                       1.09 (0.76--1.59)
                                                                    4--7 y (*n* = 243)          465             62                       1.01 (0.71--1.43)

Test for trend *p* = 0.50; sum of patient years and number of fractures in analysis stratified by exposure duration is less than in the main analysis as follow up censored at 7 y in stratified analysis.

Discussion {#s5}
==========

In these data we have found an increased risk of fracture in users of thiazolidinediones. Our results suggest that the increased risk applies to both men and women and is observed at a wide range of fracture sites. In addition, we were able to look at the effects of treatment duration on fracture risk, and our results suggest the risk may increase steadily with exposure duration up to 7 y. The risk estimate with pioglitazone was comparable to that seen with rosiglitazone at each fracture site, although the results for pioglitazone failed to reach statistical significance given that relatively fewer patients registered in the GPRD receive pioglitazone. While a clear mechanism for a deleterious effect of thiazolidinediones on bone has not been identified, a recent review has highlighted a number of preclinical studies in which rosiglitazone was associated with an increase in bone loss [@pmed.1000154-Murphy1].

A key advantage of this study was the use of the self-controlled case-series design, which is much less prone to problems of confounding than traditional case-control or cohort designs. Between-patient differences are of little relevance since the risk comparisons are made entirely within patients. Also, the self-controlled case series is often more efficient in terms of power than other observational study designs and so more precise estimates of effects can be made.

Other main strengths of the study were that it was large and statistically powerful. Our study was based on routine clinical data from the UK GRPD, which is representative of the population of the UK and so the results are likely to be highly generalisable. The validity of fracture recording in the GPRD has been shown to be high, and drug-related fractures have been the subject of several studies within this database [@pmed.1000154-vanStaa1]--[@pmed.1000154-Hubbard1]. A potential weakness might relate to the quality of the clinical data. Drug prescriptions in the GPRD are generated by practice computers, ensuring the accuracy of the electronic prescribing records. Prescription data were highly detailed and recorded prior to people developing fracture so there was no potential for recall bias. It is possible that some patients were not taking their prescribed thiazolidinediones during periods we assigned as exposed; however, we believe the likelihood of widespread low adherence in patients with a serious illness such as diabetes is unlikely and this would tend to dilute any true effect estimate for thiazolidinedione exposure.

We also acknowledge there are inherent difficulties in determining whether a recorded diagnosis in the GPRD is truly incident or a repeat record of a previous diagnosis. We aimed to do this by excluding from the analysis all fractures occurring within 6 mo of a previous fracture at the same site. This approach may lead to an overestimate in the number of incident fractures and so we conducted a sensitivity analysis where only the first ever fracture recorded for each patient was included. This made no material difference to our results.

The validity of the self-controlled case-series method relies on the independence of the decision to initiate treatment and the risk of the outcome. For this study, it requires that the decision to prescribe a thiazolidinedione is independent of whether a patient has ever had a fracture and their perceived risk of having a fracture at a later date. It also assumes the decision to start a thiazolidinedione is not temporally correlated with other exposures that influence the risk of fractures (e.g., corticosteroid therapy). If these assumptions are invalid, the results presented here could reflect confounding whereby a change in the underlying risk of fractures is temporally associated with a decision to change a patient\'s oral antidiabetic therapy. Although it seems implausible that the decision to prescribe a thiazolidinedione would be related to a change in the underlying risk of fracture, we conducted an analysis using exposure to sulphonylureas as a control to investigate this further. This analysis shows what happens to a patient\'s risk of fracture on commencing a new class of oral antidiabetic, and we found no evidence of an increase in age-adjusted fracture risk. This finding suggests confounding is unlikely to explain the results seen with thiazolidinediones, and that the effect we report here may be a direct effect of the drug. One would need to think of a form of time-varying confounding that applied to commencing one form of oral antidiabetic treatment (glitazones) but not to another (sulphonylureas) to be concerned that the thiazolidinedione results are due to unmeasured time-varying confounding. The static results over time for sulphonylureas also suggest the analysis has successfully adjusted for age, otherwise we would expect to see the relative risk increasing with sulphonylurea exposure period. In addition, the sensitivity analysis restricting each patient\'s observation period to the 2 y before and after first thiazolidinedione prescription attempted to remove some of the effect of age from the analysis and gave similar results to the main analysis, which again suggests age was adequately accounted for in these analyses.

We explored whether the choice of observation period could have introduced bias to the results with sensitivity analyses. Publication of the ADOPT trial in 2006 first highlighted fracture as a possible risk with rosiglitazone and could have led to a change in prescribing habits. An analysis restricted to observations before publication had no material effect on our results. Secondly, thiazolidinediones first became available in 2000; an analysis restricted to observations from 2000 onwards also had no material effect on the results, suggesting our choice of observation period was robust to these factors.

Consideration must be given to other possible sources of bias. Patients hospitalized following a fracture could continue thiazolidinedione therapy but prescriptions issued in hospital would not be recorded in the GPRD and such periods would therefore be missing from our analysis. The resulting underestimate of thiazolidinedione exposed time would lead to an overestimate of the risk during exposed periods. We therefore looked for evidence of apparent thiazolidinedione discontinuation postfracture. Less than 1% of patients in our study discontinue their thiazolidinedione within 30 d of a fracture, indicating this is unlikely to be a major source of bias. Similarly, bias can be introduced with this form of case-series analysis if a substantial proportion of the events of interest are fatal. The exact cause of death can be difficult to establish using GPRD records. Nonetheless we noted that death was recorded for 155 patients in this study. Of these, 88 had their final fracture before starting a thiazolidinedione and only 11 (0.5%) had a fracture during the 30 d prior to death. This result suggests fatal fractures were rare in this study and therefore unlikely to lead to substantial bias. The sensitivity analysis excluding patients who died confirms this as the results were very similar to the main analysis.

Because the risk of fractures changes substantially as people become older, it is important that our analysis adequately controlled for the effect of age. We therefore adjusted for age at the date of fracture, in single-year bands. The self-controlled case-series method facilitates fine adjustments for age at every stage of the analysis by stratifying follow-up time on a combination of drug exposure and age. Of vital importance, patient age at first thiazolidinedione prescription varied widely, and so although each individual patient is older during their exposed period, both exposed and unexposed states are fully represented in each age band. We are confident that the increased risk of fractures detected with thiazolidinediones is unlikely to be the effect of residual confounding by age because the distinct lack of an association with sulphonylurea exposure suggests our approach successfully accounted for age.

The overall increased risk seen in our study is slightly smaller than the near doubling of risk seen in clinical trials, although this may reflect differences in treatment duration. We have found that the relative risk of fracture appears to increase with treatment duration, and the median treatment duration in the ADOPT study was 4 y [@pmed.1000154-Kahn1], compared with a mean duration of 2 y in our study. Of most importance, the risk we have identified appears to be nonspecific in terms of fracture site or gender, in contrast with the trials that reported a risk predominantly in women, affecting bones in the hand, arm, wrist, and foot [@pmed.1000154-Kahn1],[@pmed.1000154-US1]. However, these differences may be due to a lack of power in the clinical trials to detect fractures at less frequently affected sites, or in men, who generally have a lower rate of fractures than women [@pmed.1000154-vanStaa3].

The recently published RECORD randomized clinical trial of rosiglitazone versus metformin or a sulphonylurea also reported an increased risk of fractures associated with rosiglitazone treatment (overall risk ratio: 1.57, 95% CI 1.26--1.97) [@pmed.1000154-Home2]. Fractures were more common in women than men, and upper/lower limbs were the sites most commonly affected. Very few hip and spine fractures were reported, precluding firm conclusions about any effect of glitazones at these sites. Although the study was not designed or powered to study fractures, the results appear broadly consistent with those reported here.

The large number of patients included in our study allowed us to look in detail at the effect of treatment duration, and our results suggest the increased risk of fractures is present within a year of starting thiazolidinedione treatment, and the relative risk appears to increase with continued treatment. This finding is of particular relevance as the absolute risk of fractures with serious sequelae (e.g., hip and vertebrae) increases dramatically with age [@pmed.1000154-Meier1], and an additional increasing risk associated with thiazolidinediones is likely to be of concern in patients at high baseline risk of fractures. Of note, the age at first thiazolidinedione prescription was 10 y greater in our study than the age at first exposure in the ADOPT trial of rosiglitazone and so the absolute increase in fractures would be substantially higher amongst this more elderly "real-world" population than the absolute increase seen in clinical trials. To demonstrate how our findings would affect patients with different underlying fracture risks we have taken age- and sex-specific fracture rates from the GPRD calculated by van Staa et al. [@pmed.1000154-vanStaa3] and applied the relative rate for all fractures of 1.43 measured in the present study. In men aged 50--55 y, treatment with a thiazolidinedione could be expected to increase the rate of all fractures by around 28 per 10,000 patient years. By contrast, in women aged 80--85 y the rate of fractures could increase by 125 per 10,000 patient years.

A recent case-control study based on the GPRD also identified an increased risk of fractures associated with thiazolidinedione use [@pmed.1000154-Meier1]. However, this study relied on comparisons between people rather than within person. The reasons why someone might be prescribed or not prescribed thiazolidinediones are likely to be multiple and complex. In addition, it is likely that at least some of the differences between people exposed and not exposed could be related to the risk of future health outcomes, including fractures. Between-person comparisons are therefore potentially prone to selection bias and confounding due to factors that are unknown or difficult to measure and control for. While broadly similar, the risk estimates in the study by Meier et al. were somewhat higher than those observed in our own study, possibly suggesting an element of residual confounding in the case-control study. It is notable that in the case-control study, only 47 of the people with fractures and 119 people in the control comparison group had been exposed to a thiazolidinedione as the study focused on a narrow range of fracture types. This result compares to the 1,819 people with fractures who had been exposed to a thiazolidinedione included in our study.

We have demonstrated an increased risk of fractures associated with thiazolidinedione treatment. The increased risk was observed with both rosiglitazone and pioglitazone, in both men and women, and for a wide range of fracture sites including the hip. The risk increases with treatment duration. These findings should be taken into consideration in the wider debate surrounding the possible risks and benefits of treatment with thiazolidinediones.
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